Détails du produit
Synonym
MMP2, CLG4, CLG4A, MMP-II, MONA, TBE-1
Source
Mouse MMP-2 Protein, Fc Tag (MM2-M5253) is expressed from human 293 cells (HEK293). It contains AA Ala 30 - Cys 662 (Accession # P33434-1). It needs to be activated by agents such as APMA in vitro to have hydrolytic activity.
Predicted N-terminus: Ala 30
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 97.5 kDa. The protein migrates as 95-110 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Supplied as 0.2 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
Shipping
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Storage
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE

Mouse MMP-2 Protein, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS

The purity of Mouse MMP-2 Protein, Fc Tag (Cat. No. MM2-M5253) is more than 90% and the molecular weight of this protein is around 185-235 kDa verified by SEC-MALS.
Report
Bioactivity
Measured by its ability to cleave the fluorogenic peptide substrate Mca-PLGL-Dpa-AR-NH2. The specific activity is >800 pmol/min/µg (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire

Introduction de fond
Progrès de frontière
- Nom anglais:
Matrix metalloproteinase-2
- Catégorie:
- Nombre de médicaments répertoriés:
0 Détails
- Nombre de médicaments cliniques:
1 Détails
- Étape de développement la plus élevée:
Phase 1 Clinical



















